Research programme: mRNA based therapeutics - Omega Therapeutics/Stanford University School of Medicine
Alternative Names: mRNA therapeutics - Omega Therapeutics/Stanford University School of MedicineLatest Information Update: 03 Nov 2021
At a glance
- Originator Omega Therapeutics; Stanford University School of Medicine
- Class Eye disorder therapies; RNA
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 18 Oct 2021 mRNA based therapeutics is available for licensing as of 18 Oct 2021. https://omegatherapeutics.com/our-portfolio/#pipeline
- 14 Oct 2021 Omega Therapeutics signs research collaboration with Stanford University School of Medicine for Omega epigenomic controllers
- 14 Oct 2021 Early research in Eye disorders in USA (Parenteral)